PSMA Radioligand Therapy in Prostate Cancer
Ludmila Santiago Almeida, Elba Etchebehere, Irene García Megías, Adriana K. Calapaquí Terán, Boris Hadaschik, Patrick M. Colletti, Ken Herrmann, Francesco Giammarile, Roberto C. Delgado Bolton
Abstract
ABSTRACT: Diagnosis and treatment of prostate cancer are complex and very challenging, being a major health care burden. The efficacy of radioligand therapy with prostate-specific membrane antigen agents has been proven beneficial in certain clinical indications. In this review, we describe management of prostate cancer patients according to current guidelines, especially focusing on the available clinical evidence for prostate-specific membrane antigen radioligand therapy.
Topics & Concepts
MedicineRadioligandProstate cancerGlutamate carboxypeptidase IIManagement of prostate cancerProstateOncologyCancerInternal medicineReceptorProstate Cancer Treatment and ResearchRadiopharmaceutical Chemistry and ApplicationsProstate Cancer Diagnosis and Treatment